To OTC Journal Members:
 

How Are We Doing So Far This Year?

The OTC Journal has published 33 editions so far this year, today's being #34. We have focused most of our attention on three companies, each of whom we believe are still good candidates to provide exciting returns for investors from today's levels. In fact, of the 33 editions published, 60% have featured one or more of the three companies.

Until today's relief rally, the market has been extremely ugly since the first week of March. The Bear Market has now extended for more than two years, frustrating investors. It has become a market of individual stocks. You can find isolated issues that are doing extremely well, but large cap stocks continue to be pounded.

Below find a quick review of our performance in 2001 on each of the three companies. We are currently reviewing several candidates for new profiles, but nothing is planned right now. In the meantime, we believe each of these stocks is poised for appreciation, especially when this protracted Bear Market ends.
 

Cross Media Marketing (AMEX: XMM)

As we stated in our January 2nd Edition, we believed Cross Media Marketing would be our best risk/reward ratio idea of 2002, and the stock's performance has proven us right.

Opening the year at $9.14, the stock has been up 63% at its high, and today is trading 46% above its January 2nd closing price. This performance is even more impressive when compared to the Dow Jones Advertising Index, which is down 2% on the year.

The stock is now up almost exactly 100% since our November 5, 2001 coverage launch. This is nearly a 200% annualized return, a powerful result in these market conditions.

More importantly, we believe this stock has much further upside. Our price target for 2002 is $20. Louis Martin of Taglich Brothers has a $25 price target on the stock. Our price projection is based solely on the company's prediction it will achieve $1.29 in Earnings Per Share this year, with a 100% growth rate in revenues.

Cross Media is issuing March quarterly financial results just before the market opens tomorrow. We will cover the earnings release in the weekend edition.

In the interest of full disclosure, we inform you that one of our editors owns 3000 shares of Cross Media in his own personal account, purchased in the open market with a cost basis of $9.185. Our editor is free to buy and sell the stock any time at his own discretion. This should be viewed as a potential conflict of interest.
 

Diomed Holdings (AMEX: DIO)

Despite the battering the Biotech sector has experienced since the first week of March, shares of Diomed have held up well. The stock made its all time low of $3.81 on March 21st. Since that day shares of Diomed have appreciated 16% while the Biotech Index has been hammered by 23%.

We introduced the company to you on February 22nd when it opened on the American Stock Exchange at $6.95. The stock traded as high as $9 twice since launching the profile, giving short term traders a nice return.

There was unprecedented early interest in the stock, with over $4 million in volume daily. The stock probably traded up a little too high in the early stages. However, this company now has two FDA Approvals, and sales should double this year.

The company's revolutionary new treatment for Varicose Veins could easily take the company to the $50 million level in sales in 2003, and we believe the stock could see $10 this year as more evidence unfolds concerning market penetration of their EVLT (EndoVenous Laser Treatment) product.
 
 

XML Global Technologies (OTC BB: XMLG)

XML's chart looks like a roller coaster, having gone from $.20 last October, to $.75 last January, to $.20 last month, and now rebounding to the $.30 level.

This is by far the riskiest company we cover, but could also provide the highest percentage gain over the remainder of the year for risk oriented investors.

XML has develped software which many view as the Holy Grail of the next generation of B to B solutions. The company's XML software solutions act as a kind of Universal Translator which allow computer systems to communicate with each other. The company has been prominently featured in both Business Week and Investors Business Daily.

Since reincarnating coverage on April 19th, the stock has appreciated 30% while the software index has dropped 12%. 

At this stage the company needs to raised additional capital. An annoucement along those lines would be great news for shareholders, and we hope it is just around the corner. Our target price for this stock in 2002 is $1, predicated on the company raising additional capital.

SwingWire.com also has a lucrative incentive model for experienced investors and traders who consistently outperform the market. Share market ideas with other like-minded investors, establish a proven track record, provide insightful commentary, attract followers and ultimately become one of the Internet's highest paid and most sought after CyberAnalysts! 

Click here to receive your FREE 30-Day Trial Membership with no further obligation. Sign Up Today! 
 

Click Here to view our compensation on every company we have ever covered, or visit the following web address:  http://www.otcjournal.com/disclaimer.html for our full profiles and http://www.otcjournal.com/trading-alerts/disclaimer.html for Trading Alerts.

MarketByte LLC has been paid a fee of $100,000 in cash and 250,000 options convertible into free trading shares, exercisable at $3.50, by Mohammed Patel, an individual, for publishing information on Diomed Corp for a period of one year. MarketByte LLC has been paid the following fee by XML Global for a year of representation extending from February 2, 2001 to February 2, 2002: $100,000 cash, 60,000 shares of free trading stock, 60,000 shares of restricted stock which are now free trading, and 60,000 options exercisable at $2. The 60,000 shares of free trading stock have been contributed by a third party on behalf of the company. MarketByte's contract to represent the company expired February 2, 2002. The contract was renewed for another year, and XML Global has paid compensation of $20,000 in cash and agreed to tender one million shares of newly issued restricted common stock. Please review our policy on selling shares found in our Mission Statement on our Home Page.

All statements and expressions are the sole  opinions of the editors and are subject to change without notice. A profile, description, or other mention of a company in the newsletter is neither an offer nor solicitation to buy or sell any securities  mentioned. While we believe all sources of information to be factual and reliable, in no way do we represent or guarantee the accuracy thereof, nor the statements made herein.

The editor, members of the editor's family, and/or entities with which they are affiliated, are forbidden by company policy to own, buy, sell or otherwise trade stock for their own benefit in the companies who appear in the publication unless specifically disclosed in the newsletter.

The profiles, critiques, and other editorial content of the OTCjournal.com may contain forward-looking statements relating to the expected capabilities of the companies mentioned herein.

THE READER SHOULD VERIFY ALL CLAIMS AND DO THEIR OWN DUE DILIGENCE BEFORE INVESTING IN ANY SECURITIES MENTIONED. INVESTING IN  SECURITIES IS SPECULATIVE AND CARRIES A HIGH DEGREE OF RISK. THE INFORMATION FOUND IN THIS PROFILE IS PROTECTED BY THE COPYRIGHT LAWS OF THE UNITED STATES AND MAY NOT BE COPIED, OR REPRODUCED IN ANY WAY WITHOUT THE EXPRESSED, WRITTEN  CONSENT OF THE EDITORS OF OTCjournal.com.

We encourage our readers to invest carefully and read the investor information available at the web sites of  the Securities and Exchange Commission ("SEC") at http://www.sec.govand/or the National Association of Securities Dealers ("NASD") at http://www.nasd.com. We also strongly recommend that you read the SEC advisory to investors concerning Internet Stock Fraud, which can be found at  http://www.sec.gov/consumer/cyberfr.htm. Readers can review all public filings by companies at the SEC's EDGAR page. The NASD has published information on how to invest carefully at its web site.